FDA Fast Track Designation for BH-30643 for the Treatment of Advanced EGFR C797S-positive NSCLC
“Fast Track designation is an important regulatory milestone and reflects FDA’s recognition, based on its review of our preliminary data, of the potential for BH-30643 to address a significant unmet medical need in this molecularly defined population, for which no oral targeted therapies are approved,” said Geoff Oxnard, M.D., Chief Medical Officer of BlossomHill Therapeutics. “Receiving this designation reaffirms our confidence in the development strategy for BH-30643 as a novel EGFR inhibitor designed to overcome C797S-mediated resistance. It also provides opportunities for more frequent engagement with FDA and potential access to other expedited programs, including potential eligibility for rolling review and accelerated approval, if applicable criteria are met.”
Share:
More News
“These regulatory clearances represent an important milestone for FL-261 and our strategy to expand targeted alpha therapy into various solid tumors,” said Debora Barton, MD, Chief Medical Officer of Full-Life Technologies. “[225Ac]Ac-FL-261 is designed to selectively target c-MET-expressing tumors by delivering potent alpha radiation directly into the tumor sites. We
“This financing, together with FDA clearance of the IND, marks an important inflection point for TwoStep and positions us to advance TS-104, our lead peptide-drug conjugate, through Phase 1 clinical development in oncology. This trial will provide the first clinical evaluation of the multi-specific targeting approach at the heart of
“This is a very different way of thinking about how we treat cancer,” said Michael Verneris, MD, professor of pediatric oncology at CU Anschutz and program co-leader of Tumor-Host Interactions at the CU Anschutz Cancer Center. “We wanted to find targets that are present across many different cancers rather than
“People being treated for small cell lung cancer are already navigating an aggressive and difficult-to-treat disease, and the time required to receive and monitor treatment can add to that burden for both patients and care centers,” said Jay Bradner, M.D., executive vice president, Research and Development, Artificial Intelligence and Data